Exenatide has potential as disease modifying agent in Parkinson's disease
Tuesday, May 6, 2014 - 18:38
in Health & Medicine
A follow-up study of patients with Parkinson's disease (PD) who participated in an earlier 'proof of concept' clinical trial using exenatide showed that improvements persisted 12 months after discontinuing exenatide therapy. These data provide strong encouragement for the further study of this drug in patients with PD, report researchers.